1. Home
  2. PYPD vs LNSR Comparison

PYPD vs LNSR Comparison

Compare PYPD & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PolyPid Ltd.

PYPD

PolyPid Ltd.

HOLD

Current Price

$5.21

Market Cap

107.0M

Sector

Health Care

ML Signal

HOLD

Logo LENSAR Inc.

LNSR

LENSAR Inc.

BUY

Current Price

$6.71

Market Cap

106.6M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
PYPD
LNSR
Founded
2008
2004
Country
Israel
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical Electronics
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
107.0M
106.6M
IPO Year
2014
2005

Fundamental Metrics

Financial Performance
Metric
PYPD
LNSR
Price
$5.21
$6.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
★ $11.75
$11.33
AVG Volume (30 Days)
★ 82.0K
53.9K
Earning Date
11-11-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.61
Revenue
N/A
★ $58,435,000.00
Revenue This Year
N/A
$4.90
Revenue Next Year
N/A
$18.71
P/E Ratio
★ N/A
$10.77
Revenue Growth
N/A
★ 9.24
52 Week Low
$3.06
$4.95
52 Week High
$5.73
$12.94

Technical Indicators

Market Signals
Indicator
PYPD
LNSR
Relative Strength Index (RSI) 50.34 38.62
Support Level $4.18 $5.42
Resistance Level $5.59 $8.73
Average True Range (ATR) 0.24 0.28
MACD -0.02 -0.11
Stochastic Oscillator 42.55 18.31

Price Performance

Historical Comparison
PYPD
LNSR

About PYPD PolyPid Ltd.

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

About LNSR LENSAR Inc.

LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia (excluding South Korea), South Korea, and Other.

Share on Social Networks: